Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Statement

17 Aug 2006 07:44

Stanelco PLC17 August 2006 Stanelco PLC17 August 2006 Stanelco PLC ("Stanelco" or "the Company") 17 August 2006 Trading update The Company announced on the 14th July 2006 in its interim results for the sixmonth period ending 30 April 2006 that its closing cash position at 30 April2006 was GBP0.3m. The Company started the period with a cash balance of GBP4.4mand made investments in research and development of GBP0.6m and increased itslevels of stock from GBP2.6m at the year end to GBP3.1m. The Company alsoinvested GBP1.2m in capital expenditure in the period. Since the half year end, the Company raised GBP3.7m (net of expenses) by way ofan equity placing in June 2006 of which GBP1.6m was used to meet a stage paymentfor the acquisition of Biotec and GBP2.1m was for working capital purposes. Ofthat GBP2.1m, GBP2.0m has been used for the ongoing commercialisation of theGroup's technologies and meeting the Group's operational running expenses since1 May 2006, and GBP0.1m has been used for capital expenditure. The Company also stated in those interim results that it was considering itsfunding requirements and funding options for the next phase of its development.As at today's date the Company has cash at bank of GBP0.9m with an unusedoverdraft facility of GBP0.2m. The Company estimates that its current cash at bank of GBP0.9m, together withprojected receivables and working capital needs is sufficient to meet its cashrequirements for a further three months in the absence of further funding or newrevenue streams commencing in the period. Since 2000, Stanelco's business model has transformed from a manufacturer andsupplier of capital goods into an intellectual property company with interestsin markets with significant growth potential, which include sustainablepackaging and environmentally responsible sealing solutions for the packagingindustry. As indicated in the interim results, in order to enable the Group to move intothe next phase of the commercialisation of its intellectual property portfolioand to meet its working capital requirements, the Company is currently exploringall financing options including a public equity issue. The Company will update the market once any further information is available. Martin Wagner, Stanelco Chief Executive said: "While the Company is exploring all of its financing options, it continues toactively progress the commercialisation of its products. The Company is in advanced negotiations with a number of potential joint venturepartners in the USA to compound biodegradable resin. This is to meet thedemands currently expressed to Stanelco by major multiple retailers and globalfast food chains. Letters of intent with two of these companies have beenexchanged and the Company believes that these will lead to contracts in theshort term. We acknowledge that Stanelco has encountered delays in rolling out GREENSEAL tothe market. The delays have primarily resulted from the limitations of the foodpackaging industry to allow access to machines to test the technology in afactory environment. The Board believes that these delays will not impact onthe potential success of the project." Contact Martin WagnerChief Executive02380 867 100 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jan 20157:00 amRNSOperational Update
22nd Jan 20157:00 amRNSPre-close Trading Statement
21st Jan 20154:35 pmRNSHolding(s) in Company
11th Dec 201410:11 amRNSChange of Adviser
14th Nov 20149:58 amRNSHolding(s) in Company
4th Nov 20147:00 amRNSTrading Update
3rd Sep 20147:00 amRNSInterim Results
12th Aug 20149:36 amRNSHolding(s) in Company
31st Jul 20147:00 amRNSContract progress for RF Technologies Business
24th Jul 20143:28 pmRNSTrading Update
6th Jun 20143:56 pmRNSHolding(s) in Company
7th May 20147:00 amRNSEMI Share Option Plan
23rd Apr 201412:26 pmRNSResult of AGM and Appointment of Director
23rd Apr 20147:00 amRNSTrading Update
31st Mar 20147:00 amRNSUpdated Corporate Presentation
28th Mar 20147:02 amRNSPosting of Notice of AGM & Annual Report
27th Mar 20147:00 amRNSPreliminary Results
24th Mar 201411:43 amRNSContract for Stanelco RF Technologies Division
19th Feb 20149:01 amRNSHolding(s) in Company
24th Jan 20147:00 amRNSPre-close Trading Statement
4th Dec 20133:37 pmRNSIssue of Shares to Director
28th Nov 20131:30 pmRNSDirector/PDMR Shareholding
27th Nov 20137:00 amRNSHolding(s) in Company
4th Nov 20137:00 amRNSTrading Update
31st Oct 201312:27 pmRNSTotal Voting Rights
2nd Oct 201312:47 pmRNSIssue of Shares to a Director
27th Sep 20138:51 amRNSTR-1: Notification of Major Interest in Shares
25th Sep 201312:33 pmRNSResult of General Meeting
2nd Sep 20137:10 amRNSNotice of General Meeting
2nd Sep 20137:00 amRNSInterim Results
26th Jul 20137:00 amRNSPurchase of Shares following Consolidation
18th Jul 20137:00 amRNSInterim Management Statement
20th Jun 20132:34 pmRNSIssue of Equity
20th Jun 201312:45 pmRNSResult of General Meeting
17th Jun 201312:01 pmRNSHolding(s) in Company
17th Jun 201311:59 amRNSHolding(s) in Company
23rd May 20137:01 amRNSCapital Reorganisation
23rd May 20137:00 amRNSSettlement with Landlord in Respect of Leases
26th Apr 20137:00 amRNSIssue of shares to a Director Total Voting rights
25th Apr 20134:10 pmRNSResult of AGM
25th Apr 20137:00 amRNSTrading Update
4th Apr 20137:00 amRNSResearch Grant Award
3rd Apr 20134:35 pmRNSNotice of AGM and Annual Report and Accounts
28th Mar 20137:10 amRNSDirector's Remuneration and Consultancy agreement
28th Mar 20137:01 amRNSPreliminary Results
23rd Jan 20137:00 amRNSPre-close Trading Statement
2nd Nov 20127:00 amRNSTrading Update
1st Oct 20123:24 pmRNSCompletion of Sale
27th Sep 20122:03 pmRNSResult of General Meeting
7th Sep 20127:00 amRNSProposed Sale of stake in Biotec Holding GmbH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.